Ambrx Takes Advantage of Large Molecule Frenzy
This article was originally published in Start Up
Executive Summary
Ambrx $52 million July 2006 Series C financing underscores recent increased interest in second-generation protein technologies and suggests that interest comes from an ever-wider group of investors.